Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 0.79
(-5.94%)
SEK 0.79
(-5.94%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 83.16 Million SEK | 10.97% |
| 2022 | 75.99 Million SEK | 157.44% |
| 2021 | 29.51 Million SEK | -40.81% |
| 2020 | 49.87 Million SEK | 5.0% |
| 2019 | 47.49 Million SEK | 7.27% |
| 2018 | 44.28 Million SEK | 53.77% |
| 2017 | 28.79 Million SEK | 21.88% |
| 2016 | 23.62 Million SEK | 42.96% |
| 2015 | 16.52 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 21.67 Million SEK | 0.0% |
| 2023 Q3 | 19.54 Million SEK | -9.84% |
| 2023 Q4 | 19.54 Million SEK | 0.0% |
| 2023 FY | 84.32 Million SEK | 10.97% |
| 2023 Q1 | 21.67 Million SEK | 17.4% |
| 2022 Q4 | 18.46 Million SEK | 0.0% |
| 2022 Q2 | 18.47 Million SEK | 0.0% |
| 2022 Q1 | 18.47 Million SEK | 15.63% |
| 2022 FY | 75.99 Million SEK | 157.44% |
| 2022 Q3 | 18.46 Million SEK | -0.04% |
| 2021 Q2 | 15.24 Million SEK | 0.0% |
| 2021 FY | 29.51 Million SEK | -40.81% |
| 2021 Q1 | 15.24 Million SEK | 24.14% |
| 2021 Q4 | 15.97 Million SEK | 0.0% |
| 2021 Q3 | 15.97 Million SEK | 4.8% |
| 2020 Q3 | 12.27 Million SEK | 6.58% |
| 2020 Q2 | 11.52 Million SEK | -12.54% |
| 2020 Q1 | 13.17 Million SEK | -45.59% |
| 2020 FY | 49.87 Million SEK | 5.0% |
| 2020 Q4 | 12.27 Million SEK | 0.0% |
| 2019 Q2 | 12.47 Million SEK | 15.38% |
| 2019 Q1 | 10.81 Million SEK | -56.71% |
| 2019 FY | 47.49 Million SEK | 7.27% |
| 2019 Q4 | 24.21 Million SEK | 86.73% |
| 2019 Q3 | 12.96 Million SEK | 3.94% |
| 2018 Q2 | 10.35 Million SEK | 15.61% |
| 2018 FY | 44.28 Million SEK | 53.77% |
| 2018 Q4 | 24.97 Million SEK | 185.37% |
| 2018 Q3 | 8.75 Million SEK | -15.45% |
| 2018 Q1 | 8.95 Million SEK | 1.26% |
| 2017 Q3 | 6.58 Million SEK | -1.55% |
| 2017 Q1 | 6.68 Million SEK | 5.82% |
| 2017 FY | 28.79 Million SEK | 21.88% |
| 2017 Q4 | 8.84 Million SEK | 34.27% |
| 2017 Q2 | 6.68 Million SEK | 0.0% |
| 2016 Q4 | 6.32 Million SEK | 0.0% |
| 2016 FY | 23.62 Million SEK | 42.96% |
| 2015 FY | 16.52 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 72.917% |
| Ziccum AB (publ) | 27.87 Million SEK | -198.332% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -407.097% |
| BioArctic AB (publ) | 89.62 Million SEK | 7.205% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -95.086% |
| Mendus AB (publ) | 129.13 Million SEK | 35.596% |
| Genovis AB (publ.) | 88.19 Million SEK | 5.701% |
| Intervacc AB (publ) | 79.78 Million SEK | -4.241% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -370.333% |
| Active Biotech AB (publ) | 44.8 Million SEK | -85.608% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 38.807% |
| Aptahem AB (publ) | 10.01 Million SEK | -730.615% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 74.131% |
| Kancera AB (publ) | 63.07 Million SEK | -31.853% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 38.253% |
| Fluicell AB (publ) | 28.61 Million SEK | -190.628% |
| Saniona AB (publ) | 1.07 Million SEK | -7622.284% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1046.526% |
| Biovica International AB (publ) | 133.72 Million SEK | 37.805% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -320.258% |
| AcouSort AB (publ) | 25.87 Million SEK | -221.414% |
| Xintela AB (publ) | 57.31 Million SEK | -45.106% |
| Abliva AB (publ) | 27.86 Million SEK | -198.46% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 57.019% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1406.958% |
| OncoZenge AB (publ) | 15.9 Million SEK | -422.911% |
| Amniotics AB (publ) | 29.07 Million SEK | -186.079% |
| 2cureX AB (publ) | 36.51 Million SEK | -127.748% |
| CombiGene AB (publ) | 44.14 Million SEK | -88.403% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -467.59% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 94.507% |
| Camurus AB (publ) | 1.05 Billion SEK | 92.151% |
| Corline Biomedical AB | 30.16 Million SEK | -175.686% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -43.318% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1044.318% |
| I-Tech AB | 40.14 Million SEK | -107.156% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 90.323% |
| Cyxone AB (publ) | 28.21 Million SEK | -194.779% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 23.955% |
| Biosergen AB | 26.8 Million SEK | -210.228% |
| Cantargia AB (publ) | 290.01 Million SEK | 71.323% |
| NextCell Pharma AB | -576.01 Thousand SEK | 14538.586% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 54.236% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -193.61% |
| Nanologica AB (publ) | 69.88 Million SEK | -19.005% |
| SynAct Pharma AB | 224.49 Million SEK | 62.953% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -88.267% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -247.199% |
| LIDDS AB (publ) | 27.75 Million SEK | -199.687% |
| Lipum AB (publ) | 37.3 Million SEK | -122.931% |
| BioInvent International AB (publ) | 441.4 Million SEK | 81.158% |
| Alzinova AB (publ) | 36.39 Million SEK | -128.511% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 71.296% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -958.632% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 27.725% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -279.854% |
| Simris Alg AB (publ) | 38.64 Million SEK | -115.23% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 41.835% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 76.744% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 25.015% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -465.776% |